arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

CRISPR Therapeutics AG

CRSP
$48.57 ▼ -3.22 (-6.22%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
47 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CRISPR Therapeutics AG faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7B
Dividend Yield —
Revenue Growth 1325.1% ↗
Op. Margin None
ROIC -5.8% ↘
FCF / Share $-0.93 ↘
Trailing P/E —
Price / Book 2.9x
FCF Yield —
Debt / Equity 0.36
info Valuation on last close. End-of-day price, Nov 5, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.67M
↑ +1325.1% —
Net Income Profit after all expenses
$-122.93M
↑ +9.6% —
Operating Margin Operating profit as % of sales
-181.0%
↓ -623.3% —
FCF / Share Free cash flow per share
$-0.93
— -0.4% —
Long-Term Debt Long-term obligations
$586.93M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
23
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 47 quarters